

Kristen K Patton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6718770/publications.pdf>

Version: 2024-02-01

84
papers

4,989
citations

136950

32
h-index

91884

69
g-index

87
all docs

87
docs citations

87
times ranked

6905
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis. <i>JAMA Cardiology</i> , 2022, 7, 175.	6.1	22
2	CE-522-04 MORTALITY AND MORBIDITY OF CARDIAC SARCOIDOSIS: AN INTERNATIONAL REGISTRY. <i>Heart Rhythm</i> , 2022, 19, S28-S29.	0.7	1
3	CI-569-02 CONDUCTION SYSTEM PACING FOR CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH HEART FAILURE. <i>Heart Rhythm</i> , 2022, 19, S97.	0.7	0
4	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009203.	4.8	14
5	Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009344.	4.8	3
6	Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2021, 144, e41-e55.	1.6	47
7	Premature ventricular complexes: diagnostic and therapeutic considerations in clinical practice. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 57, 5-26.	1.3	36
8	Risk of Adverse Cardiovascular Events in Cardiac Sarcoidosis Independent of Left Ventricular Function. <i>American Journal of Cardiology</i> , 2020, 127, 142-148.	1.6	9
9	Guidance for Rebooting Electrophysiology Through the COVID-19 Pandemic From the Heart Rhythm Society and the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008999.	4.8	6
10	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2020, 141, 1915-1926.	1.6	40
11	Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. <i>Circulation</i> , 2020, 141, e823-e831.	1.6	122
12	Lead extraction for reduction of chronic pain related to cardiovascular implantable electronic device. <i>Europace</i> , 2019, 21, 781-786.	1.7	4
13	Device Therapy and Arrhythmia Management in Left Ventricular Assist Device Recipients: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e967-e989.	1.6	104
14	2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary. <i>Heart Rhythm</i> , 2019, 16, e227-e279.	0.7	44
15	2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. <i>Journal of the American College of Cardiology</i> , 2019, 74, e51-e156.	2.8	411
16	Competitive athletes with implantable cardioverter-defibrillators—How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry. <i>Heart Rhythm</i> , 2019, 16, 581-587.	0.7	27
17	Cybersecurity for Cardiac Implantable Electronic Devices. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1284-1288.	2.8	64
18	Subcutaneous ICD screening with the Boston Scientific ZOOM programmer versus a 12-lead ECG machine. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 511-516.	1.2	10

#	ARTICLE	IF	CITATIONS
19	Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 978-982.	1.7	20
20	Putting the "Informed" in the informed consent process for implantable cardioverter-defibrillators: Addressing the needs of the elderly patient. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 312-320.	1.2	4
21	Initial experience with a novel electrophysiology mapping simulator. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 197-202.	1.2	5
22	Anesthesia and SCD implantation "When less (invasive) may be more. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 817-819.	1.2	0
23	Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study). <i>Stroke</i> , 2018, 49, 980-986.	2.0	112
24	What We Know, What We Think We Know, and What We Do Not Know at All. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006245.	4.8	1
25	2017 ACC/HRS Lifelong Learning Statement for Clinical Cardiac Electrophysiology Specialists. <i>Journal of the American College of Cardiology</i> , 2018, 71, 231-250.	2.8	4
26	Moral Distress at the End of a Life: When Family and Clinicians Do Not Agree on Implantable Cardioverter-Defibrillator Deactivation. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 530-534.	1.2	12
27	Cardiac sarcoidosis: Diagnosis confirmation by bronchoalveolar lavage and lung biopsy. <i>Respiratory Medicine</i> , 2018, 144, S13-S19.	2.9	20
28	Hardwired for Life? Implantable Defibrillator Dilemmas in Older Patients. <i>American Journal of Medicine</i> , 2018, 131, 1143-1145.	1.5	4
29	Acute myocarditis following high-dose interleukin-2 treatment. <i>Journal of Cardiology Cases</i> , 2017, 15, 28-31.	0.5	4
30	2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. <i>Heart Rhythm</i> , 2017, 14, e97-e153.	0.7	308
31	Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 767.	6.1	59
32	Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. <i>International Journal of Cardiology</i> , 2017, 241, 457-462.	1.7	41
33	Changes in Depressive Symptoms and Subsequent Risk of Stroke in the Cardiovascular Health Study. <i>Stroke</i> , 2017, 48, 43-48.	2.0	39
34	HRS Clinical Document Development Methodology Manual and Policies: Executive summary. <i>Heart Rhythm</i> , 2017, 14, e495-e500.	0.7	16
35	2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. <i>Heart Rhythm</i> , 2017, 14, e503-e551.	0.7	792
36	Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When is the Most Clinically Relevant Time to Evaluate? "Reply. <i>JAMA Cardiology</i> , 2017, 2, 1397.	6.1	0

#	ARTICLE	IF	CITATIONS
37	Assessment and the Competencies: A Faculty Development Game. <i>Journal of Graduate Medical Education</i> , 2016, 8, 442-443.	1.3	1
38	Outcomes in Patients With Congenital Heart Disease Receiving the Subcutaneous Implantable-Cardioverter Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 615-622.	3.2	26
39	Electrocardiographic Early Repolarization. <i>Circulation</i> , 2016, 133, 1520-1529.	1.6	97
40	Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. <i>JAMA Cardiology</i> , 2016, 1, 900.	6.1	127
41	Improved Survival Using a Quadripolar Cardiac Resynchronization Lead. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 434-437.	3.2	1
42	Development and Validation of a Sudden Cardiac Death Prediction Model for the General Population. <i>Circulation</i> , 2016, 134, 806-816.	1.6	97
43	Concomitant Use of the Subcutaneous Implantable Cardioverter Defibrillator and a Permanent Pacemaker. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1240-1245.	1.2	35
44	COCATS 4, the 2015 CCEP Advanced Training Statement, and the Transition From 12 to 24 Required Months of Electrophysiology Training. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 120-123.	3.2	4
45	Association Between Left Atrial Abnormality on ECG and Vascular Brain Injury on MRI in the Cardiovascular Health Study. <i>Stroke</i> , 2015, 46, 711-716.	2.0	69
46	Management of Arrhythmias in Cardiac Sarcoidosis. <i>Clinical Cardiology</i> , 2015, 38, 635-640.	1.8	8
47	HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. <i>Heart Rhythm</i> , 2015, 12, e69-e100.	0.7	449
48	Ejection Fraction Improvement After Primary Prevention Defibrillator Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 532-534.	2.8	1
49	From Bradycardia to Tachycardia: Complete Heart Block. <i>American Journal of Medicine</i> , 2015, 128, 702-706.	1.5	4
50	Changes in Depressive Symptoms and Incidence of First Stroke Among Middle-Aged and Older US Adults. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	43
51	Defibrillator Therapy in Chronic Kidney Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 774-776.	4.8	8
52	Socioeconomic Determinants of Cardiovascular Disease: Recent Findings and Future Directions. <i>Current Epidemiology Reports</i> , 2014, 1, 89-97.	2.4	18
53	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1968-1969.	2.8	1
54	Unexpected Deviation in Circadian Variation of Ventricular Arrhythmias. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2702-2708.	2.8	34

#	ARTICLE	IF	CITATIONS
55	Fibroblast Growth Factor-23 and Incident Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 298-307.	1.6	123
56	N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. <i>Heart</i> , 2013, 99, 1832-1836.	2.9	103
57	Early life predictors of atrial fibrillation-related mortality: Evidence from the health and retirement study. <i>Health and Place</i> , 2013, 21, 133-139.	3.3	8
58	In Anticipation of Grief. <i>Circulation</i> , 2013, 128, 2725-2728.	1.6	2
59	Does the association between depressive symptoms and cardiovascular mortality risk vary by race? Evidence from the Health and Retirement Study. <i>Ethnicity and Disease</i> , 2013, 23, 155-60.	2.3	27
60	Fine-Mapping and Initial Characterization of QT Interval Loci in African Americans. <i>PLoS Genetics</i> , 2012, 8, e1002870.	3.5	13
61	Inappropriate Mode Switching in a Dual-Chamber Defibrillator System. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, e67-8.	4.8	2
62	Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2012, 126, 2402-2407.	1.6	66
63	The impact of height on the risk of atrial fibrillation: the Cardiovascular Health Study. <i>European Heart Journal</i> , 2012, 33, 2709-2717.	2.2	89
64	Wenckebach Periodicity at Rest That Normalizes With Tachycardia in a Family With a NKX2.5 Mutation. <i>American Journal of Cardiology</i> , 2012, 110, 1646-1650.	1.6	14
65	Elevated depressive symptoms and incident stroke in Hispanic, African-American, and White older Americans. <i>Journal of Behavioral Medicine</i> , 2012, 35, 211-220.	2.1	30
66	N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. <i>Heart Rhythm</i> , 2011, 8, 228-233.	0.7	45
67	Early-Life Antecedents of Atrial Fibrillation: Place of Birth and Atrial Fibrillation-Related Mortality. <i>Annals of Epidemiology</i> , 2011, 21, 732-738.	1.9	9
68	Arrhythmias in Pregnancy and Postpartum. , 2011, , 339-354.		0
69	Response:. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 123-123.	1.2	0
70	The Riddle of Nonsustained Ventricular Tachycardia and Sudden Cardiac Death. <i>Circulation</i> , 2010, 122, 449-451.	1.6	2
71	REVIEW: Cardiovascular Implantable Electronic Devices in Athletes. <i>Cardiovascular Therapeutics</i> , 2010, 28, 327-336.	2.5	2
72	N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation. <i>Circulation</i> , 2009, 120, 1768-1774.	1.6	269

#	ARTICLE	IF	CITATIONS
73	Ventricular Tachycardia in a Patient with Inclusion Body Myositis. PACE - Pacing and Clinical Electrophysiology, 2009, 32, e36-9.	1.2	8
74	Atrial Lead Dysfunction: An Unusual Feature of Hypothyroidism. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1650-1652.	1.2	3
75	Catheter Ablation of Peri-AV Nodal Atrial Tachycardia from the Noncoronary Cusp of the Aortic Valve. Journal of Cardiovascular Electrophysiology, 2008, 19, 231-237.	1.7	60
76	Pharmacological therapy of atrial fibrillation. Expert Opinion on Investigational Drugs, 2007, 16, 169-179.	4.1	13
77	P2-78. Heart Rhythm, 2006, 3, S164-S165.	0.7	0
78	P2-69. Heart Rhythm, 2006, 3, S161-S170.	0.7	0
79	C-Reactive Protein in Lone Atrial Fibrillation. American Journal of Cardiology, 2006, 97, 1346-1350.	1.6	78
80	Clinical Subtypes of Lone Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 630-638.	1.2	41
81	Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. Journal of the American College of Cardiology, 2005, 45, 82-86.	2.8	156
82	Optimizing the defibrillation vector with a right-sided implantable cardioverter-defibrillator. Heart Rhythm, 2004, 1, 756.	0.7	1
83	Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheterization and Cardiovascular Interventions, 2003, 60, 458-461.	1.7	82
84	Sarcomere Protein Gene Mutations in Hypertrophic Cardiomyopathy of the Elderly. Circulation, 2002, 105, 446-451.	1.6	311